...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer.
【24h】

A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer.

机译：立体定向放射疗法治疗I期非小细胞肺癌的II期研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: The outcome of stage I non-small cell lung cancer (NSCLC) patients treated with conventional radiotherapy is inferior to that of patients treated surgically. We aimed to evaluate the clinical outcome of stereotactic body radiotherapy (SBRT) in the treatment of stage I NSCLC. MATERIALS AND METHODS: We performed SBRT for 31 stage I NSCLC patients. Of these, 20 were medically inoperable, and 11 refused surgery. Nineteen tumours were T1-stage masses, and 12 tumours were T2. Median tumour size was 25mm. SBRT was administered as 45Gy/3 fractions; however, when the tumour was close to an organ at risk, 60Gy/8 fractions were used. These doses were prescribed at the centre of the tumours. RESULTS: The median duration of observation for all patients was 32 months (range, 4-87 months). In 9 of the 31 cases, local recurrence was observed. The 3-year local control rates of T1 and T2 tumours were 77.9% and 40.0%, respectively. The 3-year overall and cause-specific survival rates were 71.7% and 83.5%, respectively. Although the symptoms improved with medical treatment, 5 patients developed acute pulmonary toxicity grade 2. CONCLUSIONS: SBRT is safe and effective for stage I NSCLC patients. However, a more intensive treatment regimen should be considered for T2 tumours.
机译：背景与目的：常规放疗治疗的I期非小细胞肺癌（NSCLC）患者的治疗效果不及手术治疗。我们旨在评估立体定向放射疗法（SBRT）在I期非小细胞肺癌中的临床疗效。材料与方法：我们对31例I期非小细胞肺癌患者进行了SBRT。其中20例因医学原因无法手术，另有11例拒绝手术。 T1期肿块为19个肿瘤，T2期肿瘤为12个。中位肿瘤大小为25mm。 SBRT的剂量为45Gy / 3份;但是，当肿瘤靠近有风险的器官时，使用60Gy / 8分数。这些剂量在肿瘤中心开出。结果：所有患者的中位观察时间为32个月（范围4-87个月）。在31例中的9例中，观察到局部复发。 T1和T2肿瘤的3年局部控制率分别为77.9％和40.0％。 3年总生存率和特定原因生存率分别为71.7％和83.5％。尽管症状可以通过药物治疗得到改善，但5例患者出现了2级急性肺毒性。结论：SBRT对于I期NSCLC患者是安全有效的。但是，应考虑对T2肿瘤采用更强化的治疗方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号